Citigroup downgraded the stock rating and target price for Catalyst Pharmaceuticals on June 16, 2026.
1 report, 1 independent
Updated Jun 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup downgraded the stock rating and target price for Catalyst Pharmaceuticals on June 16, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Catalyst Pharmaceuticals
company in Coral Gables, United States
Nothing else this week.
-
Citigroup
American investment bank and financial services corporation
Related events
- Citigroup downgraded Nidec's shares from 'strong-buy' to 'hold' rating.
- Benchmark downgraded its shares from buy to hold, while Morgan Stanley and Citigroup issued rating updates.
- Citigroup and Truist Financial issued buy ratings and increased price targets for Cisco.
- Jefferies downgraded a company to hold rating, while Citigroup reaffirmed neutral and Morgan Stanley reiterated overweight ratings on shares.
- Citigroup and Morgan Stanley released price target updates regarding Mercado Pago (MELI) stock.